By Dean Seal
Shares of Iterum Therapeutics surged after federal regulators approved the use of its urinary tract infection treatment Orlynvah.
The stock was up 64% at $1.92 around noon ET, closer to where it started the year.
The clinical-stage pharmaceutical company said Friday that the Food and Drug Administration has approved its new drug application for Orlynvah as a treatment for uncomplicated urinary tract infections caused by certain microorganisms in adult women with limited or no alternative oral antibacterial treatment options.
This is the first approved indication for Orlynvah and Iterum's first FDA-approved product.
Chief Executive Corey Fishman said that with the approval, Iterum will renew efforts to land a strategic transaction involving Orlynvah.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
October 25, 2024 12:04 ET (16:04 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。